Baylor Research Institute
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 6 name spellings.
25
Ending by 2030
Jan 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 2 to 23, 2026 · next Dec 2
- 4 fees due Feb 8 to 18, 2027 · next Feb 8
- 1 fee due Apr 13, 2027The maintenance fee for Establishment of patient- or person-specific cardiac myocyte cell lines from human induced pluripotent stem cells (iPSCs) (US 9,155,765) comes due Apr 13, 2027. Unpaid by Oct 13, 2027, it lapses early.
- 1 fee due May 7, 2027The maintenance fee for Fusion Proteins Comprising an ANTI-CD40 Antibody and Cancer Antigens (US 11,806,390) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
- 1 fee due Jun 30, 2027The maintenance fee for Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer (US 10,519,506) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells (US 9,234,040) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
- 1 fee due Aug 25, 2027The maintenance fee for Antagonistic anti-OX40L antibodies and methods of their use (US 10,570,208) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
- 3 fees due Oct 7 to 19, 2027 · next Oct 7
Recent changes
- 1 of the patents on this record was granted since Aug 20, 2026
- 1 term has ended since Aug 20, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,786,267 | Multivariable Antigens Complexed with Targeting Humanized Monoclonal Antibody In force · High confidence | In force | High confidence | |
| US 8,586,052 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells In force · From the USPTO record | In force | From the USPTO record | |
| US 9,234,040 | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells In force · From the USPTO record | In force | From the USPTO record | |
| US 8,728,481 | Agents that Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) In force · High confidence | In force | High confidence | |
| US 9,453,074 | Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) In force · High confidence | In force | High confidence | |
| US 11,173,202 | Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) In force · Medium confidence | In force | Medium confidence | |
| US 12,016,915 | Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) In force · Medium confidence | In force | Medium confidence | |
| US 12,714,745 | Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) In force · Low confidence | In force | Low confidence | |
| US 8,080,638 | Anti-interferon alpha monoclonal antibodies and methods for use In force · From the USPTO record | In force | From the USPTO record | |
| US 10,279,030 | Agents That Engage Antigen-Presenting Cells Through Dendritic Cell Asialoglycoprotein Receptor (DC-ASGPR) In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 55: 10 patents in force now held by others · 15 lapsed for an unpaid fee · 26 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
11 pending · 29 abandoned · 91 no status recorded